USA flag logo/image

An Official Website of the United States Government

An Immunoadhesin Therapy for Gastrointestinal Anthrax

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93451
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI084300
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PLANET BIOTECHNOLOGY, INC.
25571 CLAWITER RD HAYWARD, CA 94545-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: An Immunoadhesin Therapy for Gastrointestinal Anthrax
Agency: HHS
Contract: 1R43AI084300-01
Award Amount: $159,096.00
 

Abstract:

DESCRIPTION (provided by applicant): The development of anthrax countermeasures has focused almost exclusively on the perceived threat of inhalational anthrax. However, preparing a sufficiently fine powder of Bacillus anthracis spores for aerosol distribut ion requires a high degree of technical sophistication. A simple and more credible threat may come from deliberate contamination of food just prior to consumption, so-called salad bar bioterrorism . Gastrointestinal anthrax, caused by ingestion of B. anth racis spores, can be as deadly as inhalational anthrax and does not respond well to antibiotic treatment, the only therapy currently available. Planet Biotechnology Inc has developed a recombinant immunoadhesin protein, PBI-220, that is remarkably effectiv e at protecting rabbits against inhalational anthrax. PBI-220 is a fusion of CMG2 (the high affinity human anthrax toxin receptor) with human IgG Fc, which we are producing in both transiently and stably transformed plants. In this proposal we wish to deve lop a rabbit model for gastrointestinal anthrax and determine the efficacy of PBI-220 in that model. In addition we propose to engineer a new immunoadhesin comprised of CMG2 and the Fc of human IgA, co-expressed in plants with human J chain. We plan to use this new immunoadhesin to exploit the natural ability of the body to transport polymeric IgA from the circulation to the lumen of the gut, and in so doing demonstrate another therapy for gastrointestinal anthrax. PUBLIC HEALTH RELEVANCE: The American publ ic is vulnerable to a bioterrorist attack using Anthrax (Bacillus anthracis). We believe than an immunoadhesin, comprised of the human anthrax toxin receptor CMG2 and a human IgG or IgA Fc, can provide complete protection against anthrax after the developm ent of symptoms, without the need for vaccination, and would allow the development of the body's own protective antibodies against Bacillus anthracis.

Principal Investigator:

Keith Wycoff
5108871461
KWYCOFF@PLANETBIOTECHNOLOGY.COM

Business Contact:

Elliott Fineman
efineman@planetbiotechnology.com
Small Business Information at Submission:

PLANET BIOTECHNOLOGY, INC.
PLANET BIOTECHNOLOGY, INC. 25571 CLAWITER RD HAYWARD, CA 94545

EIN/Tax ID: 770392393
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No